RCS - N4 Pharma PLC - New Corporate Presentation

N4 PharmaAnnouncement

11/06/2024 11:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240611:nRSK9877Ra&default-theme=true

RNS Number : 9877R  N4 Pharma PLC  11 June 2024

 

N4 Pharma plc

 ("N4 Pharma" or the "Company")

 

New Corporate Presentation

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, is
pleased to announce that a new Corporate Presentation has been published.

 

The Corporate Presentation can be viewed on the Company's interactive investor
hub, at:
https://investors.n4pharma.com/activity-updates/n4-pharma-company-presentation-june-24
(https://investors.n4pharma.com/activity-updates/n4-pharma-company-presentation-june-24)

 

 

For more information please contact:

 

 N4 Pharma plc                                                                  investors.n4pharma.com (http://investors.n4pharma.com)

 Nigel Theobald, CEO

 Luke Cairns, Executive Director
 SP Angel Corporate Finance LLP                                                 Tel: +44(0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                                          Tel: +44(0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope
 InvestorHub                                                                    https://investors.n4pharma.com/link/YeNdZP

                                                                              (https://investors.n4pharma.com/link/YeNdZP)
 Engage with us by asking questions, watching video summaries and seeing what
 other shareholders have to say.

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel
antigens in these fields to use Nuvec® as the delivery vehicle for these
antigens. As these products progress through pre‐clinical and clinical
programs, N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at
https://investors.n4pharma.com/auth/signup
(https://investors.n4pharma.com/auth/signup) .

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAEKFFFSLEFA